FT : Amber Capital makes move to oust Lagardère board

Amber Capital makes move to oust Lagardère board
Activist presses for reforms at underperforming French media group

Activist investor Amber Capital is seeking to oust the board of Lagardère at its forthcoming annual shareholder meeting, the latest stage in its long-running campaign for change at the underperforming family-controlled media group. 

Amber, which has been increasing its position in Lagardère and is now the group’s largest shareholder with a 16.4 per cent stake, unveiled its board proposal as part of a 49-page presentation. It argued that poor governance had allowed heir and managing partner Arnaud Lagardère to destroy shareholder value for years with no consequences for his position. 

“The current board has failed its shareholders,” said Amber’s founder Joseph Oughourlian. “We will start by changing the board and implement change from there.”

To that end, the activist fund has proposed 16 resolutions to put forward a slate of eight new board members at the AGM in May. It will not oppose the appointment of two new members that Lagardère has proposed. They are former French president Nicolas Sarkozy, a family friend of Mr Lagardère and of his late father Jean-Luc Lagardère, and Guillaume Pepy, who used to run SNCF, France’s state-owned rail company.

Amber has selected Patrick Sayer, the well-respected former CEO of listed private equity company Eurazeo, as its candidate for board chairman. 

The move represents an escalation in the conflict that has raged between Lagardère and Amber since it first took a stake in 2016. It also comes as the group’s businesses, which include publisher Hachette, the Relay chain of travel retail stores and Paris Match magazine, are being hit by the economic shock of the coronavirus pandemic. This prompted Lagardère to suspend its annual profit guidance on Wednesday and cut its dividend by 30 per cent.

Lagardère shares are down 61 per cent in the past year, compared with a 19 per cent decline in France’s blue-chip CAC 40 index.

A spokesman for Lagardère declined to comment on Amber’s board proposals. In the past, Lagardère has accused Amber of seeking to destabilise the company and its leadership, and has sued the hedge fund for defamation in the French courts.

Whether Amber’s campaign will be successful at the May 5 annual meeting will depend on whether other large shareholders, including the Qatar Investment Authority, can be rallied to the cause. Other activists have taken aim at Lagardère in the past but their efforts failed in large part because of the grip that the company’s structure gives to Mr Lagardère.

Although he owns only 7.5 per cent of the company, Mr Lagardère controls the group though an unconventional structure known as a société en commandite par actions, which is a hybrid between a partnership and a limited liability company. In practice this means that the shareholders — or limited partners — cannot remove the general partner — Mr Lagardère — as they could in a normal company. 

Amber Capital has argued that the structure has meant that there are few outside checks on Mr Lagardere’s power and no consequences for strategic mis-steps and poor capital allocation. 

Amber is hoping to change that by replacing the board and then enacting a far-reaching turnround plan that would eliminate the commandite structure and get rid of Mr Lagardère and his longstanding lieutenants. Amber also wants to cut management costs so as to invest more in publishing and travel retail.

Two years ago Amber tried unsuccessfully to nominate two members to
Lagardère's board at its shareholder meeting, but QIA and other investors voted against its proposals.

So far the fund has lost money on its investment in Lagardère. It bought most of its shares when the price was around €18 to €20 per share, compared to the current price of €9.50.

>>> US After Hours Summary: SCVL +9.9%, MU +5.7% up on earnings; RDFN

After Hours Summary: SCVL +9.9%, MU +5.7% up on earnings; RDFN -5.3% as it says home-buying demand has slowed notably

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: SCVL +9.9%, MU +5.7%, FUL +0.3%

Companies trading higher in after hours in reaction to news: NBLX +5.9% (approves a 73% reduction of the quarterly distribution), GRFS +3.8% (to collaborate with US govt to produce COVID-19 treatments), VIR +3.2% (enters into license agreement with XNCR for use of Xtend in treatment of COVID-19), AVB +3.1% ( withdraws 2020 outlook), AAL +3.1% (has borrowed $1 bln in term loans), HBI +2.2% (withdraws Q1 and FY20 guidance), HPQ +1.9% (shares letter to shareholders regarding pandemic and XRX offer), SBRA +0.2% (cuts dividend by 33%)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: YRD -1.1%

Companies trading lower in after hours in reaction to news: RDFN -5.3% (home-buying demand has slowed notably since March 18 update), CIO -5.3% (cuts dividend), MCFT -5% (suspends manufacturing operations; withdraws FY20 guidance), BYD -2.8% (suspends dividend, withdraws FY20 adj. EBITDAR guidance), TWO -2.3% (sells substantially all of its portfolio of non-Agency securities), F -2% (S&P lowers ratings to 'BB+' (junk)), LTC -1.4% (terminates share repurchase plan), SPWR -0.6% (withdraws FY20 guidance, implements initiatives to manage its cost structure), WYND -0.4% (withdraws 2020 guidance, suspends share buybacks)

>>> US Close Dow +2.39% S&P +1.15% Nasdaq -0.45% Russell +1.26%

Closing Stock Market Summary

The S&P 500 was up as much as 5.1% on Wednesday, as investors continued to buy beaten-up shares of companies after the Senate agreed to a revised stimulus plan, but the market faltered into the close amid some political drama and profit taking. The benchmark index finished up 1.2% for the session. 

The Dow Jones Industrial Average (+2.4%) outperformed on the back of Boeing (BA 158.73, +31.05, +24.3%). The Russell 2000 increased 1.3%, while Nasdaq Composite declined 0.5%. 

An agreement was reached in the early hours of the morning, but a vote in the Senate was delayed today due to a minor drafting error in the bill. There was some hope that the House would then approve the bill with a unanimous consent resolution despite lingering complaints in order to provide financial relief for Americans and businesses as soon as possible. 

All S&P 500 sectors were on pace to close in positive territory, but sentiment soured after Senator Sanders threatened to hold up the coronavirus bill and demand new restrictions on the $500 billion fund for corporations. Rep. Alexandria Ocasio-Cortez also warned she may oppose the unanimous consent resolution, which could further delay financial relief.  

The stimulus isn't going to help slow down the rate of coronavirus infections, but it may speed an economic recovery if the nationwide efforts to curb the virus prove successful. Granted, there's still uncertainty about that outlook, but the market has gotten anxious about getting funding to the businesses and workers who need it most right now.

By session's end, eight of the 11 S&P 500 sectors still closed higher, led by the industrials (+5.3%), energy (+4.5%), and real estate (+4.5%) sectors. The communication services sector (-1.6%) was dragged lower by an acknowledgement from Facebook (FB 156.21, -4.77, -3.0%) that it has seen a weakening in its ads business.

Boeing shares surged 24%, as the company stands to benefit from the stimulus bill that will rescue the airline industry. Reports indicated the company could also receive direct aid from Washington and that the company aims to restart production of the 737 MAX by May.  

Nike (NKE 79.01, +6.68, +9.2%) shares rose 9% after the company beat revenue estimates and said it's seeing improving market conditions in China, Japan, and Korea. Apple (AAPL 245.52, -1.36, -0.6%) slipper lower with the broader market and amid a Nikkei Asian Review report suggesting it might consider delaying the launch of the 5G iPhone by months.

U.S. Treasuries finished mixed with shorter-dated maturities posting gains that drove yields on the four-week bill (-6 bps to -0.05%) and three-month bill (-4 bps to -0.03%) negative. The 2-yr yield declined seven basis points to 0.30%, while the 10-yr yield increased four basis points to 0.86%. The U.S. Dollar Index declined 1.2% to 100.86. WTI crude rose 2.5%, or $0.60, to $24.53/bbl. 

Reviewing Wednesday's economic data:

  • February durable goods orders increased 1.2% (consensus -1.4%). Excluding transportation, durable goods orders declined 0.6% (consensus -0.2%).
    • The key takeaway from the report is that business spending was soft in February, which is disappointing in and of itself, but all the more disappointing knowing that it is going to collapse now in the face of the shutdown measures adopted to stop the spread of the coronavirus.
  • The FHFA Housing Price Index increased 0.3% in March after increasing 0.6% in February.
  • The weekly MBA Mortgage Applications Index dropped 29.4% following an 8.4% decline in the prior week.

Looking ahead, investors will receive the weekly Initial and Continuing Claims report, the third estimate for Q4 GDP, and the Advance reports for International Trade in Goods, Retail Inventories, and Wholesale Inventories for February on Thursday.

  • Nasdaq Composite: -17.7%
  • S&P 500: -23.4%
  • Dow Jones Industrial Average: -25.7%
  • Russell 2000: -33.5%

FT : Gilead asks to rescind special status for potential coronavirus drug

Gilead asks to rescind special status for potential coronavirus drug
Drugmaker had come under fire for ‘orphan’ ranking that conferred pricing and tax benefits

Gilead Sciences has asked US regulators to rescind “orphan drug” status for its potential coronavirus treatment, after it was criticised by activists for abusing a process reserved for medicines for rare diseases. 

The company’s unusual U-turn on its potential coronavirus candidate Remdesivir comes just two days after Gilead disclosed it had been granted the status by the US Food and Drug Administration. The drugmaker said on Wednesday that it was waiving all benefits of the status — which include significant tax incentives and control over prices for at least seven years in a de facto monopoly.

On Tuesday the Financial Times reported that activists had slammed the designation, calling it “morbid calculus” in the face of a rapidly-spreading pandemic. Orphan drugs are intended for diseases affecting up to 200,000 people in the US. Almost 60,000 people are infected with coronavirus in the US, but the number is likely to be an underestimate. Globally, more than 436,000 people have been infected. 

“Gilead is confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir, without the orphan drug designation,” the company said on Wednesday.

Activists had criticised the timing of the move, which was disclosed hours after the drugmaker said it would be limiting some of its compassionate-use supplies.

“Gilead acknowledged it did not file for orphan status until early March, after it was clear it was a pandemic,” said Jamie Love, founder of intellectual property advocacy group Knowledge Ecology International.


“Gilead’s decision can fix one problem, but we don’t know what other drugs will qualify for orphan status. The FDA made the mistake, and the FDA procedures need to be fixed,” added Mr Love.

The FDA’s decision to grant orphan drug status had prompted anger in Congress, where some US lawmakers expressed concern that the company could use it to make remdesivir unaffordable to many coronavirus patients.

Before Gilead made its reversal, Patty Murray, the most senior Democrat on the Senate health committee, said the FDA decision had raised “some concerning flags”, adding that she planned to push the agency as to why it had made the determination.

Many analysts believe remdesivir, originally developed to treat Ebola, is one of the best bets for treating Covid-19. Studies in animals have also shown it is successful against other coronaviruses. 

Data from a small study using the drug to treat Covid-19 patients in China is expected to be released in the coming weeks. Large trials of hundreds of patients have been started by the World Health Organization and the US National Institutes of Health, among others. 

Gilead’s U-turn comes after AbbVie, a US pharma company that makes a combination of HIV drugs that are also being tested against the virus, waived all intellectual property rights on the combination worldwide, paving the way for lower-priced generics to flood the market.

SKY : Coronavirus: 'Game changer' COVID-19 tests could be available in days, MPs

Coronavirus: 'Game changer' COVID-19 tests could be available in days, MPs told
The tests, which look similar to pregnancy tests, could be ordered on Amazon or taken at high street branches such as Boots.

Millions of new coronavirus testing kits could be ready to order on Amazon in days, rather than weeks or months, according to Public Health England.
Prime Minister Boris Johnson has previously spoken of a simple test for coronavirus as a potential "total game changer" in the battle against COVID-19.
Sponsored link

    Professor Sharon Peacock, director of the National Infection Service at Public Health England, revealed on Wednesday that millions of such a test have been ordered and could be used "in the near future".
    They would show whether an individual had antibodies for COVID-19 which, if they did, would mean they could return to work if they were not showing symptoms.
    Evidence suggests people cannot catch coronavirus twice in quick succession, if they have already been infected and recovered, the government has said.

    The tests, which look similar to pregnancy tests, could be ordered on Amazon or taken at high street branches such as Boots, Prof Peacock said.
    The World Health Organisation has urged countries to step up testing in the global fight against coronavirus.

    REcode : Bill Gates says we can’t restart the economy soon and simply “ignore th

    Bill Gates says we can’t restart the economy soon and simply “ignore that pile of bodies over in the corner”
    Gates rebuked the proposal of leaders like Donald Trump.

    Bill Gates rebuked proposals, floated over the last two days by leaders like Donald Trump, to reopen the global economy despite the Covid-19 coronavirus outbreak, saying that this approach would be “very irresponsible.”

    Gates did not mention Trump by name, but the American president has said that he may decide to relax some of the country’s “social distancing” in order to jumpstart the country’s shut-down economy. Gates, the country’s leading philanthropist, has been among the most active tech leaders in using his resources to try and contain the virus.

    “There really is no middle ground, and it’s very tough to say to people, ‘Hey, keep going to restaurants, go buy new houses, ignore that pile of bodies over in the corner. We want you to keep spending because there’s maybe a politician who thinks GDP growth is all that counts,’” Gates said in an interview with TED Tuesday. “It’s very irresponsible for somebody to suggest that we can have the best of both worlds.”

    Trump has suggested that this middle ground would indeed be possible — by letting some healthy people return to work, for instance, while keeping more vulnerable workers in their homes. Experts have said that drastic and widespread social distancing is required to keep the pandemic from spreading further. Trump has said he would make a decision at the end of the month but has said that he believes the “cure” could be worse than the “problem itself.”

    Asked what he would do if he were president, Gates returned to his concerns about reopening the economy.

    “The economic effect of this is really dramatic. Nothing like this has ever happened to the economy in our lifetimes,” Gates said. “But bringing the economy back ... that’s more of a reversible thing than bringing people back to life. So we’re going to take the pain in the economic dimension — huge pain — in order to minimize the pain in the diseases-and-death dimension.”

    The Bill and Melinda Gates Foundation has put up $100 million for programs to fund testing and science around the pandemic, and he has begun using his public profile, too, to shape the coronavirus conversation. This month, Gates himself resigned from the board of Microsoft, which he founded, and is now effectively a full-time philanthropist — and the country’s most famous one.

    And Gates has tried to cast himself as an optimist. He has said that the social distancing measures might need to last as little as six weeks, but said that “we have no choice,” despite the economic impacts.

    “It’s disastrous for the economy,” Gates said. But “the sooner you do it in a tough way, the sooner you can undo it and go back to normal.”